Risankizumab Medicine 08 June 2021 Extended indication Patients with Atopic Dermatitis 12 Years and older. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Risankizumab Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Skin diseases Extended indication Patients with Atopic Dermatitis 12 Years and older. Current proprietary name Already available biosimilars / generics Proprietary name Skyrizi Manufacturer Abbvie Portfolio holder Mechanism of action Interleukin inhibitor Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks IL-23 remmer Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date 2022 Expected Registration Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks De fabrikant geeft aan dat het niet bekend is wanneer registratie plaats vindt doordat het proces op dit moment 'on hold' is. Therapeutic value Current treatment options Ciclosporine A, methotrexaat, azathioprine, mycofenolaat mofetil/mycofenolzuur en dupilumab Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT03706040 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 15,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Horizonscan Geneesmiddelen dupilumab; Additional remarks De prijs voor risankizumab zal waarschijnlijk vergelijkbaar zijn met dupilumab. De prijs van dupilumab voor deze leeftijdsgroep bedraagt per patiënt per jaar: €15.000,70 (uitsluitend in het eerste jaar €576,95 erbij voor een éénmalige oplaaddosis). Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks